Navigation Links
Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
Date:12/5/2013

LEXINGTON, Massachusetts, December 5, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, today announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution. OPUS-2 compared lifitegrast to placebo administered twice daily for 84 days (12 weeks) in dry eye patients with history of active artificial tear use within 30 days prior to screening. Lifitegrast met the prespecified co-primary endpoint for the patient-reported symptom of eye dryness (change in Eye Dryness Score from baseline to week 12) (p-value<0.0001). Lifitegrast did not meet the prespecified co-primary endpoint for the sign of inferior corneal staining score (change from baseline to Week 12) using fluorescein staining compared with placebo (p-value=0.6186).

"In this clinical trial, we note that lifitegrast showed a statistically significant improvement in the prespecified symptoms of dry eye disease and is the first drug to do so in a phase 3 clinical trial," said Flemming Ornskov, M.D., Chief Executive Officer, Shire. "We will be examining the totality of the data for lifitegrast in OPUS-2, as well as OPUS-1 and across the entire clinical trial program. We look forward to discussing the lifitegrast program with regulatory authorities."

The study also evaluated the safety and tolerability of lifitegrast based on occurrence of treatment-emergent adverse events (TEAEs). The most commonly reported TEAEs associated with lifitegrast were dysgeusia (altered sense of taste) (16.2% vs 0.3% for placebo), instillation site irritation (7.8% vs 1.4% for placebo), instillation site reaction (7.0% vs 1.1% for placebo) and visual acuity reduced (5.0% vs 6.4% for placebo). There were no ocular serious TEAEs or drug-related serious TEAEs. 93.2% of patients enrolled in the study remai
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MinuteClinic Opens First Clinic Locations in New Hampshire
2. Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
3. Shire to Present at the Bank of America Merrill Lynch Global Health Care Conference
4. Shire to Present at the Morgan Stanley Global Healthcare Conference
5. Shire Reports 7% Product Sales Growth: Anticipating Double Digit Non GAAP Earnings Growth in 2013
6. Shire Announces Award Recipients for 2013 US ADHD Scholarship Program
7. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
8. SARcode Bioscience Announces Acquisition by Shire US Holdings Inc.
9. Shire Acquires Premacure AB
10. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
11. Shire Supports Rare Disease Day 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
(Date:4/27/2015)... 27, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report first ... close on Monday, May 11, 2015, followed ... at 4:30pm Eastern.Conference Call & Webcast: Monday, ... Domestic: , 888-556-4997International: , 719-457-2628Conference ID: , ...
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., a ... curative treatment of chronic hepatitis B virus (HBV) infection, ... its lead HBV core inhibitor candidate, NVR 3-778, at ... the Study of the Liver (EASL) in ... of NVR 3-778 from studies performed in a humanized ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:4/27/2015)... As ISO 27001 has quickly become ... of all sizes and in all industries, Pivot Point ... for ISO 27001 certification. The information security audit firm ... for ISO 27001 certification. Pivot Point's commitment to ISO ... number of Lead Implementers and Auditors the company employs ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
(Date:4/27/2015)... PHILADELPHIA, PA (PRWEB) April 27, 2015 ... it will exhibit its wide range of market leading ... to May 7 in Geneva, Switzerland. Vitafoods Europe 2015 ... over 100 countries showcasing the latest research in such ... personalized nutrition. , FMC Health and Nutrition’s booth ...
(Date:4/27/2015)... On May 15, Mount Soma Ashram ... campaign to raise awareness of the vision of Mount ... Somesvara Temple. Ironically, when many of these people moved ... thought they were leaving the social and technological world ... of meditation, service to a higher cause, deep introspection, ...
(Date:4/27/2015)... York, NY (PRWEB) April 27, 2015 ... are creating a seamless referral process for the Health ... with chronic heart failure or diabetes, for instance, may ... most primary physicians coordinate with many other care providers. ... referring hundreds of thousands of patients each year, the ...
Breaking Medicine News(10 mins):Health News:Six Additional New ISO 27001 Lead Implementers Certified for Pivot Point Security 2Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2Health News:Mount Soma Monks Do Social Media 2Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... American Institute of Ultrasound in Medicine (AIUM) and ... the collaborative development of the Practice Guideline for ... Practice of Urology. This guideline has been developed ... the practice of urology and provides direction in ...
... Molecular Medicine (MDC) Berlin-Buch have found out why the ... the world,s most unusual mammals, feels no pain when ... in narrow dark burrows where ambient carbon dioxide (CO2) ... converted into acid, which continuously activates pain sensors. However, ...
... , TUESDAY, Dec. 20 (HealthDay News) -- Increased public ... reasons why child and teen exposure to unwanted online ... States, a new study indicates. However, reports of ... University of New Hampshire Crimes Against Children Research Center. ...
... "disarray and dysfunction" jeopardize access to medical care ... military families, said the American College of Physicians ... with House and Senate leadership. ACP is ... membership organizationin the United States, representing 132,000 internal ...
... A hike in your blood pressure during middle age significantly ... stroke during your lifetime, according to new Northwestern Medicine research. ... maintaining low blood pressure early in middle age to prevent ... developed high blood pressure in middle age or who started ...
... evaluating early kidney injuries in people, doctors monitor blood ... breakdown, to understand the severity of the injury. Creatinine ... an indication of early damage to vital kidney function. ... Missouri researchers have found that even tiny increases of ...
Cached Medicine News:Health News:MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain 2Health News:MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain 3Health News:Youth Exposure to Unwanted Internet Sexual Encounters Drops 2Health News:Congress' 'disarray' makes it 'likely' that 27 percent Medicare cut will go in effect 2Health News:New predictor of heart attack or stroke 2Health News:MU researchers find pet kidney injuries are similar to human kidney injuries 2
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... A broad selection of procedurally specific ... and allow easy access to all ... variety of approaches.,Loop Handled Graspers feature ... holds tissue firmly without tearing or ...
Medicine Products: